MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients

Background: Serum mid-regional proadrenomedullin (MR-proADM) has emerged as a marker of organ failure (mainly lungs and kidneys) and poor prognosis in patients admitted to intensive care (IC); some reports also suggest it and other markers, such as Krebs von den Lungen-6 (KL-6) and interleukin-6 (IL...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameli, Paolo, Pordon, Elena, d’Alessandro, Miriana, Marzi, Maria Laura, Galasso, Lucrezia, Biuzzi, Cesare, Bergantini, Laura, Bargagli, Elena, Scolletta, Sabino, Franchi, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296224/
https://www.ncbi.nlm.nih.gov/pubmed/37371775
http://dx.doi.org/10.3390/biomedicines11061680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296224/
https://www.ncbi.nlm.nih.gov/pubmed/37371775
http://dx.doi.org/10.3390/biomedicines11061680

Ejemplares similares